At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
SAGE-718drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating SAGE-718 for Alzheimer Disease and 2 related conditions. Completed, enrolled 26 participants across 10 sites.
Detailed Summary
The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Cognitive Dysfunction, Mild Dementia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartDec 2020
Primary CompletionSep 2021
TodayJul 2026
First PostedOct 26, 2020
Enrollment StartDec 7, 2020
Primary CompletionSep 28, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.7 years ago
Interventions
SAGE-718drug
SAGE-718 oral tablets.